FIELD: pharmaceuticals.
SUBSTANCE: invention relates to pharmaceutical industry, namely to a biocompatible sustained release drug delivery system for injecting into the vitreous cavity of the eye of a patient with dry age-related macular degeneration (AMD) for treating the dry AMD, the system comprisses from 5 mcg to 20 mcg of bevacizumab homogeneously dispersed in a carrier of polymeric hyaluronic acid and releases from 14 ng to 120 ng of bevacizumab daily for a period of from three months to six months.
EFFECT: invention provides a sustained release of a therapeutic agent without the occurrence of or the persistence of significant immunogenicity at and adjacent to the site of the intraocular implantation or injection.
6 cl, 1 dwg, 4 ex
